Scholarlink

<p>Frailty is a prevalent geriatric syndrome, but its role in cardiometabolic disease (CMD) progression remains unclear. We examined whether frailty predicted CMD transitions. We included 22,754 participants aged 50+ from the Guangzhou Biobank Cohort Study without baseline CMD. Frailty was assessed using a 35-item frailty index (FI). Cardiometabolic multimorbidity (CMM) was defined as ≥2 of type 2 diabetes, ischemic heart disease, and stroke. Cox and multistate models estimated associations of frailty with first CMD (FCMD), CMM, and mortality. During a mean follow-up of 16.4 years, 8710 developed FCMD, 2332 progressed to CMM, and 5411 died. After adjustment, multistate analyses showed that frailty accelerated transitions from health to FCMD, from FCMD to CMM, and from CMM to death (HR per 0.1 increment in FI ranging from 1.14 to 1.48). Frailty was independently associated with CMD progression and mortality. Multistate analyses highlight its dynamic role in multimorbidity, supporting routine frailty assessment in cardiometabolic prevention.</p><p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Frailty and transitions across cardiometabolic disease states: evidence from multistate models in a 16-year Chinese cohort

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月29日

查看全文
  • Rui Hang Zhang,
  • Jiao Wang,
  • Ying Wang,
  • Rui Qiang Li,
  • Ting Yu Lu,
  • Bai Jing Zhou,
  • Lin Yang,
  • Lei Su,
  • Wei Sen Zhang,
  • Tai Hing Lam,
  • Kar Keung Cheng,
  • Lin Xu

摘要

Frailty is a prevalent geriatric syndrome, but its role in cardiometabolic disease (CMD) progression remains unclear. We examined whether frailty predicted CMD transitions. We included 22,754 participants aged 50+ from the Guangzhou Biobank Cohort Study without baseline CMD. Frailty was assessed using a 35-item frailty index (FI). Cardiometabolic multimorbidity (CMM) was defined as ≥2 of type 2 diabetes, ischemic heart disease, and stroke. Cox and multistate models estimated associations of frailty with first CMD (FCMD), CMM, and mortality. During a mean follow-up of 16.4 years, 8710 developed FCMD, 2332 progressed to CMM, and 5411 died. After adjustment, multistate analyses showed that frailty accelerated transitions from health to FCMD, from FCMD to CMM, and from CMM to death (HR per 0.1 increment in FI ranging from 1.14 to 1.48). Frailty was independently associated with CMD progression and mortality. Multistate analyses highlight its dynamic role in multimorbidity, supporting routine frailty assessment in cardiometabolic prevention.